Advocacy intelligence hub — real-time data for patient organizations
CSL Behring — PHASE4
AIRNA Corporation — PHASE1
University Hospital, Bordeaux
Tessera Therapeutics, Inc. — PHASE1, PHASE2
University of Alabama at Birmingham — PHASE4
Muğla Sıtkı Koçman University
RenJi Hospital — EARLY_PHASE1
Weill Medical College of Cornell University — PHASE1
BioMarin Pharmaceutical — PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Foundation grants
Copay cards
Foundation Grants5
HealthWell Foundation — Alpha-1-antitrypsin deficiency
HealthWell Foundation
NORD Patient Assistance — Alpha-1-antitrypsin deficiency
NORD Patient Assistance
Patient Services Inc — Alpha-1-antitrypsin deficiency
Patient Services Inc
PAN Foundation — Alpha-1-antitrypsin deficiency
PAN Foundation
The Assistance Fund — Alpha-1-antitrypsin deficiency
The Assistance Fund
Copay Assistance1
Prolastin
Bayer Corporation
Prolastin
(Alpha1-proteinase inhibitor (human))Orphan drugBayer Corporation
Program Director, Clinical R&D
CSL Behring
Ronald G Crystal, MD, MD
Weill Medical College of Cornell University
📍 NEW YORK, NY
Karina Serban, MD
University of Florida, College of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine
📍 Gainesville, Florida
Klaus Kenn, Prof. Dr.
Schoen Klinik BGL
Charlie Strange, MD
Medical University of South Carolina
📍 WIGGINS, MS
Cuvelier Antoine
Pneumology - CHU Rouen, France